Abiraterone and Enzalutamide for mCRPC
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Clinical Pearls
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
- The phase III PREVAIL study looked at enzalutamide versus placebo in chemotherapy-naïve, asymptomatic patients with metastatic castration-resistant prostate cancer
- There was a statistically significant survival benefit and positive prolongation of radiographic progression-free survival in favor of enzalutamide
- Dr. Ryan believes these data will drive the eventual use of this therapy in the chemotherapy-naïve population
- Physician prescribing preferences will ultimately determine how abiraterone and enzalutamide are used
<<<
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
